24 June 2020

Featured releases: DDS2020 Digital

Featured releases were published daily, as part of our virtual event, the PVRI DDS2020 Digital.

DDS2020 Digital Live session

  • Clinical development of inhaled GB002 for the treatment of pulmonary arterial hypertension (NCT03926793), sponsored by Gossamer Bio.
    Presented by Professor Ardeschir Ghofrani, Justus-Liebig-University Giessen, Germany, whose presentation received an average score of 9/10 
  • A study of sotatercept for the treatment of pulmonary arterial hypertension (PULSAR, NCT03496207), sponsored by Acceleron
    Presented by Dr David Badesch, University of Colorado, USA, whose presentation received a score of 9/10 
  • Pharmacogenomics and placebo response in a randomised clinical trial
    Presented by Dr Kathryn Hall, Brigham and Women's Hospital, Harvard Medical School, USA, whose presentation received a score of 9/10 

Day 5: DDS2020 Digital

John Scandurra & Irene Lang - Implantable devices to improve pulmonary circulation compliance

John Scandurra, Aria CV, & Irene Lang, Medical University of Vienna, Autria
Implantable devices to improve pulmonary circulation compliance
Sponsor: Aria CV

Kelly Chin - Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: Results of the randomised controlled TRITON study (NCT02558231)

Kelly Chin, UT Southwestern, USA
Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: Results of the randomised controlled TRITON study (NCT02558231).
Sponsor: Actelion

Day 4: DDS2020 Digital

Shao-Liang Chen -PADN-5: Pulmonary arterial denervation in patients with pulmonary hypertension associated with left heart failure (NCT02220335)

Shao-Liang Chen, Nanjing First Hospital, Nanjing Medical University, China
PADN-5: Pulmonary arterial denervation in patients with pulmonary hypertension associated with left heart failure (NCT02220335)
Sponsor: Nanjing Healthy Bureau & National Science Foundation of China

Ronald Oudiz - ABI-009, an mToR Inhibitor, for patients with severe pulmonary arterial hypertension (NCT02587325)

Ronald Oudiz, Harbor-UCLA Faculty Practice Plan, USA
ABI-009, an mToR Inhibitor, for patients with severe pulmonary arterial hypertension (NCT02587325)
Sponsor: Aadi, LLC

Day 3: DDS2020 Digital

Erika Rosenzweig - A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: early experience in adolescents and adults

Erika Rosenzweig, Columbia University Medical Center, USA
A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: early experience in adolescents and adults
Sponsor: Columbia University, USA 

Hiromi Matsubara - BPA: Where does it come from, where are we and where are we going?

Hiromi Matsubara, National Hospital Organization Okayama Medical Center, Japan
BPA: Where does it come from, where are we and where are we going? 

Day 2: DDS2020 Digital

Ioana Preston: Actigraphy as a new endpoint in PAH trials

Ioana Preston, Tufts Medical Center, USA
Actigraphy as a new endpoint in PAH trials

Khodr Tello - Right heart III Study: Right ventricular haemodynamic evaluation and response to treatment (NCT03362047)

Khodr Tello, Justus-Liebig-University Giessen, Germany
Right heart III Study: Right ventricular haemodynamic evaluation and response to treatment (NCT03362047)
Sponsor: Justus-Liebig-University Giessen

Day 1: DDS2020 Digital

Luke Howard - IV iron replacement for iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) patients (NCT01447628)

Luke Howard, Imperial College London, UK
IV iron replacement for iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) patients (NCT01447628)
Sponsor: Imperial College London

Eric Austin - Tamoxifen therapy to treat pulmonary arterial hypertension (T3PAH) (NCT03528902)

Eric Austin, Vanderblit University, USA
Tamoxifen therapy to treat pulmonary arterial hypertension (T3PAH) (NCT03528902)
Sponsor: Vanderbilt University Medical Center 

dds2020.jpg

Release schedule 

We are delighted to introduce a recorded series of featured talks, which will be available as follows:

Wednesday 24 June 2020

  • Eric Austin, Vanderblit University, USA
    Tamoxifen therapy to treat pulmonary arterial hypertension (T3PAH) (NCT03528902)
    Sponsor: Vanderbilt University Medical Center 
  • Luke Howard, Imperial College London, UK
    IV iron replacement for iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) patients (NCT01447628)
    Sponsor: Imperial College London

Thursday 25 June 2020

  • Khodr Tello, Justus-Liebig-University Giessen, Germany
    Right heart III Study: Right ventricular haemodynamic evaluation and response to treatment (NCT03362047)
    Sponsor: Justus-Liebig-University Giessen
  • Ioana Preston, Tufts Medical Center, USA
    Actigraphy as a new endpoint in PAH trials

Friday 26 June 2020

  • Hiromi Matsubara, National Hospital Organization Okayama Medical Center, Japan
    BPA: Where does it come from, where are we and where are we going? 
  • Erika Rosenzweig, Columbia University Medical Center, USA
    A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: early experience in adolescents and adults
    Sponsor: Columbia University, USA 

Saturday 27 June 2020

  • Shao-Liang Chen, Nanjing First Hospital, Nanjing Medical University, China
    PADN-5: Pulmonary arterial denervation in patients with pulmonary hypertension associated with left heart failure (NCT02220335)
    Sponsor: Nanjing Healthy Bureau & National Science Foundation of China

  • Ronald Oudiz, Harbor-UCLA Faculty Practice Plan, USA
    ABI-009, an mToR Inhibitor, for patients with severe pulmonary arterial hypertension (NCT02587325)
    Sponsor: Aadi, LLC

Sunday 28 June 2020

  • John Scandurra, Aria CV, & Irene Lang, Medical University of Vienna, Austria
    Implantable devices to improve pulmonary circulation compliance
    Sponsor: Aria CV

  • Kelly Chin, UT Southwestern, USA
    Efficacy and safety of initial triple oral versus initial double oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: Results of the randomised controlled TRITON study (NCT02558231).
    Sponsor: Actelion


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg